tradingkey.logo

Biontech SE

BNTX
View Detailed Chart

96.740USD

-7.570-7.26%
Close 09/12, 16:00ETQuotes delayed by 15 min
23.26BMarket Cap
LossP/E TTM

Biontech SE

96.740

-7.570-7.26%
Intraday
1m
30m
1h
D
W
M
D

Today

-7.26%

5 Days

-13.98%

1 Month

-14.22%

6 Months

-0.74%

Year to Date

-15.10%

1 Year

-21.60%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
38 / 507
Overall Ranking
167 / 4724
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 23 analysts
Buy
Current Rating
136.529
Target Price
+41.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 642.62M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -67.77, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 205.26M shares, decreasing 2.06% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 8.04M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker SymbolBNTX
CompanyBiontech SE
CEOProf. Ugur Sahin, M.D.
Websitehttps://www.biontech.com/
KeyAI